We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$303M
AUM Growth
+$48M
Cap. Flow
+$31.8M
Cap. Flow %
10.49%
Top 10 Hldgs %
45.97%
Holding
88
New
25
Increased
24
Reduced
13
Closed
14

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$13M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$8.63M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.27M
4
CYTK icon
Cytokinetics
CYTK
+$5.46M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$4.84M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.7M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.34M
3
ESTA icon
Establishment Labs
ESTA
+$5.32M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.05M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 79.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
51
CALL
Aclaris Therapeutics
ACRS
$730M
$1.04M 0.34%
+129,100
New +$1.64M
MLYS icon
52
Mineralys Therapeutics
MLYS
$2.35B
$979K 0.32%
+62,500
New +$1.05M
THRX
53
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$872K 0.29%
+98,221
New +$964K
BCAB icon
54
BioAtla
BCAB
$5.59M
$871K 0.29%
6,500
+3,500
+117% +$630K
JSPR icon
55
Jasper Therapeutics
JSPR
$22.9M
$863K 0.28%
+47,695
New +$882K
FHTX icon
56
Foghorn Therapeutics
FHTX
$285M
$848K 0.28%
136,771
+26,780
+24% +$175K
MIST icon
57
Milestone Pharmaceuticals
MIST
$144M
$786K 0.26%
199,382
+99,382
+99% +$363K
ROIV icon
58
Roivant Sciences
ROIV
$25.2B
$738K 0.24%
+100,000
New +$823K
ESPR
59
PUT
DELISTED
Esperion Therapeutics
ESPR
$557K 0.18%
+350,000
New +$1.81M
ETNB
60
CALL
DELISTED
89bio
ETNB
$551K 0.18%
+36,200
New +$472K
PBYI icon
61
Puma Biotechnology
PBYI
$406M
$548K 0.18%
+177,349
New +$669K
NCEL
62
NewcelX Ltd
NCEL
$20.2M
$520K 0.17%
+860
New +$502K
NUVB icon
63
Nuvation Bio
NUVB
$2.24B
$415K 0.14%
250,000
– –
CBIO
64
PUT
Crescent Biopharma
CBIO
$602M
$378K 0.12%
+3,000
New +$675K
PVLA
65
Palvella Therapeutics
PVLA
$1.98B
$300K 0.1%
+3,837
New +$444K
IMTXW
66
DELISTED
Immatics N.V. Warrants
IMTXW
$270K 0.09%
187,204
– –
NAMSW icon
67
NewAmsterdam Pharma Warrant
NAMSW
$68.5K 0.02%
+37,000
New +$58.7K
SCLXW icon
68
Scilex Holding Co Warrant
SCLXW
$2.55M
$19K 0.01%
18,099
– –
RCKTW icon
69
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$12.3K ﹤0.01%
+75,000
New +$14.5K
SCLX icon
70
Scilex Holding
SCLX
$48.1M
$3.8K ﹤0.01%
13
– –
AMGN icon
71
PUT
Amgen
AMGN
$203B
– –
-20,000
Closed -$5.25M
BMY icon
72
PUT
Bristol-Myers Squibb
BMY
$127B
– –
-175,000
Closed -$12.6M
CNTX icon
73
Context Therapeutics
CNTX
$56.4M
– –
-883,654
Closed -$584K
DYN icon
74
Dyne Therapeutics
DYN
$4.04B
– –
-92,170
Closed -$1.07M
GERN icon
75
CALL
Geron
GERN
$911M
– –
-837,000
Closed -$2.03M
1 2
3
4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, Affinity Asset Advisors held 88 positions worth $303M, up 19% from $255M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Affinity Asset Advisors deployed $31.8M of net new capital in Q1 2023, opening 25 new positions and adding to 24 existing holdings. Its largest new stake was Merck: 120,000 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 81% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $5.7M trimmed.

  • Affinity Asset Advisors's largest Q1 2023 buy was Merck: 120,000 shares worth $12.8M.
  • Affinity Asset Advisors added most to Prometheus Biosciences, Inc. Common Stock in Q1 2023, an estimated $8.63M increase.
  • Affinity Asset Advisors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $5.7M.
  • Affinity Asset Advisors fully exited Rocket Pharmaceuticals in Q1 2023, selling an estimated $5.05M.
  • Affinity Asset Advisors's ten largest holdings make up 46% of its $303M portfolio in Q1 2023.
  • Affinity Asset Advisors opened 25 new positions and closed 14 in Q1 2023.
  • Affinity Asset Advisors's portfolio value rose 19% quarter-over-quarter to $303M.

Based on Affinity Asset Advisors's 13F filing for Q1 2023, filed 15 May 2023.